Form 4: Kiniksa Pharmaceuticals Insider Transactions
Insider Transaction Report
Richard S. Levy, a Director at Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares, including the acquisition of shares via options and restricted stock units.
Summary
- Richard S. Levy, a Director at Kiniksa Pharmaceuticals International, plc, reported transactions on May 29, 2026.
- These transactions include the acquisition of 2,799 Class A Ordinary Shares through the vesting of Restricted Share Units (RSUs).
- Additionally, Levy acquired 12,158 Class A Ordinary Shares through the exercise of stock options with an exercise price of $48.38.
- Following these transactions, Levy beneficially owns 21,956 Class A Ordinary Shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports routine insider transactions related to equity compensation rather than significant strategic shifts or financial performance indicators.
Positives
- Director Richard S. Levy acquired additional equity in Kiniksa Pharmaceuticals through the vesting of RSUs and the exercise of stock options, indicating continued investment and potential alignment with company performance.
- The acquisition of 12,158 shares via options suggests a belief in the company's future stock price appreciation, given the exercise price of $48.38.
Future Outlook
The filing does not contain explicit forward-looking statements or guidance. However, the exercise of stock options by a director suggests a positive outlook on the company's future stock performance.
Industry Context
StockSavvy.ai notes that insider transactions, such as those reported by Kiniksa Pharmaceuticals' director, are closely watched by investors as they can signal management's confidence in the company's prospects. This filing is typical for a publicly traded biopharmaceutical company where equity-based compensation is common.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Richard S. Levy granted power of attorney to specific individuals to execute Forms 3, 4, and 5 on his behalf for reporting securities transactions. | 09/18/2025 | Facilitates compliance with SEC reporting requirements for insider transactions. |
Stakeholder Impact
- Shareholders: The transactions may be interpreted as a sign of management confidence, potentially influencing investor sentiment.
- Employees: The reporting of equity awards and exercises is standard practice and reflects the company's compensation structure.
Key Dates
| Date | Description |
|---|---|
| 05/29/2026 | Date of earliest transaction reported and transaction date for acquisition of shares via options and RSUs. |
| 06/02/2026 | Date of filing of the Form 4. |
| 09/18/2025 | Date of execution of the Power of Attorney. |
| 05/28/2036 | Expiration date for stock options. |
Keywords
Kiniksa Pharmaceuticals, KNSA, Form 4, Insider Trading, Securities Transaction, Director, Class A Ordinary Share, Restricted Share Units, Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.